바이오테크 보도자료
-
- ENYO Pharma Announces 16 Weeks Vonafexor (EYP001) Top-Line Interim Results from Two on-going Phase 2a Studies in Chronic Hepatitis B Patients
- ENYO Pharma (ENYO), a private clinical stage biotechnology company developing innovative drug candidates, today announced positive proof of concept data from Study EYP001-203 of Vonafexor in combination with pegylated-Interferon (peg-IFN) in virem...
- 2021년 08월 02일
-
- Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress
- Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first quarter of fiscal year 2021 (period ended June 30, 2021). Based on the solid first-quarter results, the Company also confirmed i...
- 2021년 08월 02일
-
- Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialize Takeda’s nor...
- 2021년 07월 30일
-
- Prokarium Appoints Uz Stammberger as Chief Medical Officer to Drive Clinical Development in Oncology
- Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today announced the appointment of Uz Stammberger, MD, as Chief Medical Officer. In the role, Dr. Stammberger will lead the advancement of Prokarium’s...
- 2021년 07월 30일
-
- ENYO Pharma Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a Study in F2-F3 NASH Patients over 12 weeks
- ENYO Pharma (ENYO), a private clinical stage biotechnology company developing innovative drug candidates, today announced that Vonafexor met the primary and several secondary endpoints in the LIVIFY clinical study conducted in F2-F3 Non Alcoholic ...
- 2021년 07월 29일
-
- U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,[1] its Phase 2 investigational oral orexin agonist, wh...
- 2021년 07월 29일
-
- Exchanger Industries Limited Acquires HRS Heat Exchangers
- Exchanger Industries Limited (“EIL”), the Canadian market leader and globally recognized designer and manufacturer of heat transfer products for the energy, petrochemical, industrial and clean power generation sectors, has acquired HRS Heat Exchan...
- 2021년 07월 28일
-
- Everbridge Launches Industry’s First Global Critical Event Management (CEM) Certification™ Program with Formalized Standards for Enterprise Resilience
- Everbridge, Inc. (NASDAQ: EVBG) today announced the industry’s first Critical Event Management (CEM) Certification™ Program for assessing an organization’s enterprise resilience. Developed from 20 years of professional services engagements across ...
- 2021년 07월 28일
-
- Additive Manufacturer Green Trade Association Announces New Members
- The Additive Manufacturer Green Trade Association (AMGTA), a global trade organization created to promote the environmental benefits of additive manufacturing (AM), announced today that eight additional leading AM companies have joined the trade g...
- 2021년 07월 28일
-
- Prokarium Appoints Kristen Albright as Chief Executive Officer
- Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today announced the appointment of Kristen Albright, PharmD, as Chief Executive Officer. Dr. Albright is an accomplished industry leader with broad ex...
- 2021년 07월 28일
-
- Deargen Signs Agreement With Sookmyung Women’s University Research & Business Development Foundation for Licensing NASH Biomarker Technologies
- Deargen (President: Kilsoo Kang), an artificial intelligence (AI)-powered drug discovery and development company, announced that it has signed an agreement with Sookmyung Women’s University Research & Business Development Foundation for licensing ...
- 2021년 07월 28일
-
- Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer
- ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that Dr. Revati Shreeniwas has joined the company as Chief Medical Officer. In this...
- 2021년 07월 27일
-
- SpeeDx Launch Solution for SARS-CoV-2 Variant Analysis
- SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have launched a new product line of research reagents to support reflex variant analysis for circulating SARS-CoV-2 variants of concern (VOC). The rapid development of Ple...
- 2021년 07월 27일
전시회
